Releuko ® (filgrastim-ayow), a biosimilar to Neupogen ® (filgrastim), is now available in the US for the treatment of neutropenia. Releuko, a leukocyte growth factor, is indicated to: Decrease the ...
The MarketWatch News Department was not involved in the creation of this content. -- JAMP Pharma Group launches PrPexegra(R), a biosimilar alternative to the reference product PrNeulasta(R) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback